drugset
drugset / Trial / NCT00399542

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

NCT00399542 ↗

Phase 3 Completed 581 enrolled Sucampo Pharma Americas, LLC Sucampo Pharmaceuticals, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.

Timeline

Start
2005-05
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule — —

Indications

constipation disorder irritable bowel syndrome